Abstract 37P
Background
The "Hallmarks of Cancer" framework is foundational for understanding common organizational principles underlying diverse cancer types. However, the absence of a consensus gene set for cancer hallmarks leads to varied biological interpretations across studies. In this work, we established a unified cancer hallmark gene set by merging data from existing mapping resources and devising a framework for gene set mining.
Methods
We searched the NCBI PubMed database for publications from which a list of cancer hallmark genes could be extracted or reconstructed. Then, we performed a cancer hallmarks enrichment analysis on a list of differentially expressed genes between normal and tumor tissues across eleven solid tumor types.
Results
Consolidating hallmark genes from seven projects, we identified 6,763 genes associated with ten cancer hallmarks. We discovered a hallmark enrichment “fingerprint” specific to each tumor type. Notably, kidney cancers displayed the most extensive hallmark enrichment, underscoring the complexity of the disease. Hallmarks linked to immune function, such as “Evading immune destruction” and “Tumor promoting inflammation” were prominently enriched in kidney and CNS cancers (p<0.0001). “Tissue invasion and metastasis” was the single most prominent hallmark in skin and pancreatic cancers (p<0.0001), known to metastasize early. "Reprogramming energy metabolism" emerged as the hallmark particularly enriched in breast, ovarian, and uterine cancers (p<0.0001), suggesting the feasibility of metabolic approaches to target these cancers. The hallmark “Genome instability” was significantly enriched in cancers frequently associated with lifestyle choices, including colon, oesophageal, and liver cancers (p<0.05), and in cervical cancers, known to be linked to HPV infection (p<0.0001). To facilitate the analysis of cancer hallmarks, we developed an online tool (www.cancerhallmarks.com) to identify cancer-associated hallmarks from novel gene sets.
Conclusions
We established a consensus list of cancer hallmark genes and delineated unique patterns of hallmark enrichment across diverse tumors. Our findings hold potential pharmacological implications and enhance the utility of the hallmark concept as an effective organizational tool.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This project was supported by the National Research, Development, and Innovation Office (PharmaLab, RRF-2.3.1-21-2022-00015) in Hungary. O.M. was supported by the Janos Bolyai Scholarship of the Hungarian Academy of Sciences and the Hungarian Scientific Research Fund (OTKA FK147194). The support of ELIXIR Hungary (www.bioinformatics.hu) is acknowledged.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
42P - Correlation of circulating tumor cells with cancer stage
Presenter: Ana Paz
Session: Poster session 07
43P - A redesigned cell atlas of colon cancers to better assess their cellular composition
Presenter: Marine Sroussi
Session: Poster session 07
76P - Improving access to whole genome sequencing for patients with cancer of unknown primary using formalin-fixed paraffin embedded tissues and cell-free DNA
Presenter: Richard Tothill
Session: Poster session 07
77P - Whole-exome mutation profiling of cfDNA from over 2000 samples in major cancer indications
Presenter: Eric Jia
Session: Poster session 07
78P - Real-world analysis of actionable gene fusions identified by NGS and correlation with IHC in 422 patients from the community
Presenter: Husain Hatim
Session: Poster session 07
79P - Comprehensive genomic profiling provides patients access to novel matched therapies in a diverse real-world cohort of advanced lung cancer patients
Presenter: Jyoti Patel
Session: Poster session 07
80P - Development of a next-generation sequencing diagnostics recommender tool in the framework of the molecular tumor board Freiburg
Presenter: Ralf Mertes
Session: Poster session 07
81P - FINPROVE: The Finnish national study to facilitate patient access to targeted anti-cancer drugs – Preliminary data after two years of enrollment
Presenter: Katriina Jalkanen
Session: Poster session 07
82P - Clinical and molecular characteristics of gynecologic cancer patients in FINPROVE: The national phase II drug repurposing trial in Finland
Presenter: Anniina Färkkilä
Session: Poster session 07
83P - Circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in eary high risk breast cancer: The CITUCEL trial update
Presenter: Roberto Borea
Session: Poster session 07